The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for…
Read More
DIAGNOSED AND TREATED FOR THYROID CANCER? ATA® INVITES YOUR FEEDBACK ON THIS SURVEY: https://www.surveymonkey.com/r/thyroidcancerpatientsurvey The…
New Rochelle, NY, December 14, 2017—A 10-year study of more than 1,200 patients with low-risk…
Supported by ThyCa: Thyroid Cancer Survivors’ Association, Inc. and ATA The American Thyroid Association (ATA)…
Supported by ThyCa: Thyroid Cancer Survivors’ Association, Inc. and ATA Nikita Pozdeyev, M.D., Ph.D. is…
Supported by Bite Me Cancer and ATA Irene Min, M.D. is the recipient of the…
Supported by ThyCa: Thyroid Cancer Survivors’ Association, Inc. Research Grant to Trevor Angell, MD, Brigham…
ATA 2016 Meeting News Coverage From Healio/Endocrine Today Latest clinical, basic thyroid research highlighted at…
Conference News From Medscape Diabetes & Endocrinology Coverage from the American Thyroid Association (ATA) 86th…
September 20, 2016 -- Key opinion leaders, thyroid specialists, clinical and basic researchers, and young trainees will come together for five exciting and information-filled days of symposia, scientific presentations, and...
Read More
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.